19.82
Tandem Diabetes Care Inc stock is traded at $19.82, with a volume of 1.59M.
It is down -6.86% in the last 24 hours and up +18.19% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$21.28
Open:
$21.548
24h Volume:
1.59M
Relative Volume:
0.87
Market Cap:
$1.32B
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-9.4833
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
-4.34%
1M Performance:
+18.19%
6M Performance:
-35.29%
1Y Performance:
-62.90%
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TNDM
Tandem Diabetes Care Inc
|
19.82 | 1.38B | 796.00M | -136.49M | -64.24M | -2.09 |
![]()
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-10-25 | Initiated | Mizuho | Neutral |
Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-06-24 | Initiated | Bernstein | Outperform |
Oct-04-24 | Initiated | Goldman | Neutral |
Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
Aug-08-24 | Initiated | Canaccord Genuity | Buy |
May-30-24 | Initiated | Redburn Atlantic | Buy |
May-22-24 | Upgrade | Citigroup | Neutral → Buy |
Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Mar-26-24 | Upgrade | Stifel | Hold → Buy |
Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-29-23 | Initiated | UBS | Neutral |
Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jul-21-21 | Resumed | Cowen | Outperform |
May-25-21 | Initiated | Barclays | Underweight |
Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Aug-20-20 | Initiated | Wells Fargo | Overweight |
Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
Jun-18-20 | Reiterated | Raymond James | Outperform |
Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
Mar-05-20 | Initiated | Citigroup | Neutral |
Feb-06-20 | Initiated | Raymond James | Outperform |
Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-18-19 | Initiated | Guggenheim | Buy |
Oct-04-19 | Upgrade | UBS | Neutral → Buy |
May-17-19 | Reiterated | BofA/Merrill | Neutral |
May-13-19 | Initiated | SVB Leerink | Outperform |
Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
Feb-27-19 | Reiterated | Lake Street | Buy |
Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
Sep-26-18 | Reiterated | Dougherty & Company | Buy |
Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Tandem Diabetes Care Inc (TNDM) Shares Gap Down to $20.62 on May 30 - GuruFocus
Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD) - Defense World
Cetera Investment Advisers Acquires 981 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Reflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) - Yahoo Finance
Tandem Diabetes and Roche Reach a Patent Settlement - MSN
Tandem Diabetes Care’s SWOT analysis: stock faces growth hurdles amid market shifts - Investing.com Nigeria
How the (TNDM) price action is used to our Advantage - news.stocktradersdaily.com
Tandem to pay Roche $36M in patent dispute settlement - MSN
Tandem Diabetes, Roche enter patent settlement agreement - Yahoo Finance
Tandem Diabetes Care (TNDM) Settles Patent Dispute with Roche - GuruFocus
Should Tandem Diabetes Stock Stay in Your Portfolio Now? - MSN
Tandem Diabetes To Pay Roche $36 Mln To Settle Patent Infringement Claim - Nasdaq
Tandem Diabetes Agrees to Pay Roche $36 Million in Patent Infringement Deal - marketscreener.com
Tandem Diabetes Care Settles Patent Disputes with Roche - TipRanks
Tandem Diabetes Care IncEnters Settlement Agreement With Roche EntitiesSEC Filing - marketscreener.com
Infusion Pumps Market to Hit USD 15.6 Billion by 2031, Driven - openPR.com
Deutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Bank of America Corp DE Sells 127,904 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rati - GuruFocus
Where Tandem Diabetes Care Stands With Analysts - Benzinga
Citigroup Maintains Neutral Rating on Tandem Diabetes Care (TNDM) | TNDM Stock News - GuruFocus
Tandem Diabetes Care Inc (TNDM) Trading Down 4.29% on May 21 - GuruFocus
Tandem Diabetes (TNDM) Price Target Raised by Citi, Neutral Rating Maintained | TNDM Stock News - GuruFocus
BNP Paribas Financial Markets Reduces Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Global Insulin Pumps Market Report 2021-2030: Insulet, - openPR.com
Global Insulin Pumps Market Report 2021-2030: Insulet, Medtronic, and Tandem Diabetes Care are the Major Stakeholders – Focus Report Store - Barchart.com
Fortune Brands, Whirlpool, Align Technology, Tandem Diabetes, and STAAR Surgical Shares Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) Trading 3.52% Higher on May 20 - GuruFocus
Tandem Diabetes at RBC Conference: Growth and Strategic Expansion By Investing.com - Investing.com Canada
Ameriprise Financial Inc. Sells 525,159 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Investor Network: Tandem Diabetes Care, Inc. to Host Earnings Call - ACCESS Newswire
Shareholders May Be More Conservative With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) CEO Compensation For Now - simplywall.st
Insulin Pump Market Growth, Trends & Forecast 2025 | Leading key - openPR.com
TNDM Q1 Earnings Call: Product Expansion and Channel Initiatives Drive Growth Against Margin Pressures - Yahoo Finance
Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set - MassDevice
Tandem Diabetes Care gets FDA clearance for new set By Investing.com - Investing.com India
Tandem Diabetes Earnings: Despite Solid First-Quarter Results, We Expect Growth to Decelerate - Morningstar
Tandem Diabetes Care gets FDA clearance for new set - Investing.com
Tandem's Initial Growth Spurt From the Launch of Mobi Should Moderate in the Near Term - Morningstar
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – TNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineTNDM - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Tandem Diabetes Care, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineTNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc.(TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023TNDM - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Tandem Diabetes Care, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2023 – TNDM - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Tandem Diabetes Care, Inc. (TNDM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):